Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03808870
Other study ID # NBM-BMX-002
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date December 28, 2018
Est. completion date February 16, 2022

Study information

Verified date August 2023
Source NatureWise Biotech & Medicals Corporation
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

NBM-BMX is an orally available new chemical entity to inhibit HDAC8 activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. The objectives of this study are to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors (Arm A) or in combination with the standard of care treatment (i.e., concomitant RT/TMZ followed by adjuvant TMZ) in subjects with newly diagnosed glioblastoma (Arm B).


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date February 16, 2022
Est. primary completion date February 12, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: 1. Histologically or cytologically confirmed advanced, non-resectable, and/or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available, or who were not amenable to established forms of treatment. 2. Solid tumors must have measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. 3. Female or male at 20 years of age or older. 4. ECOG performance status 0 to 2. 5. Recovered from prior treatment-related toxicity to at least grade 1 with exception of grade 2 alopecia. 6. Adequate organ function as defined by the following criteria: - Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =3 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to underlying malignancy - Total serum bilirubin =1.5 x ULN (except for subjects with documented Gilbert's syndrome) - Absolute neutrophil count (ANC) = 1500/µL - Platelets = 90,000/µL - Hemoglobin = 9.0 g/dL - Serum creatinine = 2.0 x ULN 7. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment. 8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Exclusion Criteria: Subjects presenting with any of the following will not be included in the trial: 1. Major surgery or radiation therapy within 28 days of starting study treatment. 2. Systemic anti-cancer therapy within 28 days or 5 half-lives (whichever is shorter) of starting study treatment. 3. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue. 4. Current treatment on another clinical trial. 5. Spinal cord compression, carcinomatous meningitis, or leptomeningeal disease unless appropriately treated and neurologically stable for at least 4 weeks. 6. Any of the following within the 12 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack; within 6 months prior to starting study treatment for pulmonary embolus. However, upon agreement between the investigator and medical monitor, the 6-month post-event-free period for a subject with a pulmonary embolus can be waived if due to advanced cancer. Appropriate treatment with anticoagulants is permitted. 7. NYHA Class III or IV heart failure and known history of QTc prolongation or Torsade de Pointes. 8. Use of medications known to significantly prolong the QTc interval (e.g., anti-arrhythmic and psychotropic medications). 9. Hypertension that cannot be controlled by medications. 10. Current treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed). 11. Known human immunodeficiency virus (HIV)-positive and is receiving anti-retroviral therapy. 12. Positive test for hepatitis B (HBsAg) or hepatitis C (anti-HCV antibody). 13. History of receiving organ transplantation or immune disorders that require continuous immunosuppressant agent therapy. 14. Pregnancy or breastfeeding. Female subjects must be surgically sterile or be postmenopausal, or must agree to the use of effective contraception during the period of therapy. All female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment. Male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. 15. Other severe acute or chronic medical or psychiatric conditions or laboratory abnormalities that would impart, in the judgment of the investigator and/or medical monitor, excess risk associated with study participation or study drug administration, which would make the subject inappropriate for entry into this study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
NBM-BMX softgel capsules
Patients will initially receive NBM-BMX orally once a day at 100 mg per day.

Locations

Country Name City State
Taiwan National Cheng Kung University Hospital Tainan
Taiwan Taipei Veterans General Hospital Taipei

Sponsors (1)

Lead Sponsor Collaborator
NatureWise Biotech & Medicals Corporation

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose limiting toxicity (DLT) of NBM-BMX [Safety and Tolerability] Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 up to 28 days
Primary Maximum tolerated dose (MTD) of NBM-BMX [Safety and Tolerability] The MTD will be defined as the dose level at which at most one of six patients experiences a DLT after 28 days of treatment have occurred, with the next higher dose having at least 2/3 or 2/6 patients experiencing a DLT. up to 28 days
Secondary Preliminary assessment of anti-tumor activity by Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) [Efficacy] at least 8 weeks
Secondary AUC(0-last) of NBM-BMX [Pharmacokinetics] AUC(0-last): area under the plasma concentration versus time curve to the time of the last measurable concentration Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Secondary Cmax of NBM-BMX [Pharmacokinetics] Cmax: maximum plasma concentration Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Secondary Tmax of NBM-BMX [Pharmacokinetics] Tmax: time to maximum plasma concentration Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
Secondary T(1/2) of NBM-BMX [Pharmacokinetics] T(1/2): terminal elimination half-life Day 1, 8 and 15 for Cycle 1 only (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Active, not recruiting NCT02243592 - Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment
Completed NCT03445572 - Meditative Slow Breathing or Isha Kriya Meditation in Improving Cancer-Related Symptoms in Hospitalized Participants With Cancer N/A
Active, not recruiting NCT02860039 - High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant Phase 2
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Completed NCT01635413 - Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial) N/A
Completed NCT00026169 - Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Phase 1
Recruiting NCT04534075 - Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized Trial Phase 3
Active, not recruiting NCT01806129 - Reproductive Health Program in Patients With Cancer N/A
Recruiting NCT03915717 - Observational Study of Outcomes After EchoMark and EchoSure-based Free Flap Monitoring
Recruiting NCT02280161 - Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer
Recruiting NCT05520281 - Short-term Psychodynamic Psychotherapy in Serious Physical Illness N/A
Terminated NCT00532064 - Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy
Completed NCT04990882 - FAPI PET/CT Prospective Interobserver Agreement
Completed NCT01896778 - Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer N/A
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Recruiting NCT06090266 - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Recruiting NCT05886764 - Novel Outreach Methods to Increase Enrollment to Early Phase Clinical Trials N/A
Completed NCT01432431 - Spiritual Care in Improving Quality of Life of Patients, Caregivers, and Hospital Staff N/A
Completed NCT01506440 - Cognitive Assessments in Patients With Cancer Undergoing Chemotherapy